BS Identity and Score for STRENSIQ (Alexion Pharmaceuticals, Inc.)

AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.

B
BS Level
Medical Devices, Pharma & Biotech
40.8 Avg BS

Based on 587 businesses audited.

BS Detector

Medical Devices, Pharma & Biotech BS: STRENSIQ (Alexion Pharmaceuticals, Inc.) (strensiq.com)

https://strensiq.com 📍 Industry: Medical Devices, Pharma & Biotech
32 BS / 100

This is a high-substance pharmaceutical site that avoids extreme BS by virtue of heavy regulatory requirements and a niche therapeutic focus. It is dinged primarily for its technical SEO failures and the use of branded ‘patient stars’ which, while standard for the industry, borders on trust theatre. The distance between what is claimed (hope and independence) and what is proven (rigorous clinical safety data) is remarkably short.

Info Density Power-words vs. Substance ratio.
10
33% BS
Semantic Coherence Homepage promise vs. Sub-page reality.
3
15% BS
Trust & Proof Verifiable evidence vs. Trust Theatre.
4
20% BS
Commodity Fingerprint Detection of industry clichés/templates.
5
33% BS
Identity & Authority Expert verifiability & Schema depth.
10
67% BS

Implement proper ‘Drug’ and ‘Organization’ JSON-LD schema to bridge the authority gap and link to the Alexion corporate entity. Fix the heading hierarchy by replacing repetitive H2 ‘We recommend THAT YOU…’ text with unique, descriptive labels for each recommended action. Add direct citations or links to the peer-reviewed clinical trial data that supports the ‘first and only’ claim within the body text. Replace the placeholder review counts with a link to an external patient-experience platform or remove the counter to eliminate trust theatre flags.

Info Density Power-words vs. Substance ratio.
10 Impact Weight: 30 / 100
33% BS

The site exhibits high substance density due to the integration of extensive safety data and weight-based dosing protocols (mg per kg). While some headings use emotional power words like ‘live with confidence’ and ‘courage TO USE,’ the body text is grounded in technical specifics regarding side effects like lipodystrophy and calcium build-up. There is significant concept repetition in the quiz-style ‘We recommend THAT YOU…’ sections, but these lead to specific tools rather than generic fluff. Evidence of specific frameworks is present in the ‘OneSource’ patient support model and the ‘HPP STAR’ peer program.

A validator checks markup; an AI audit checks comprehension. Start your free one page AI interpretation to see how your structured data is actually interpreted by LLMs.

Semantic Coherence Homepage promise vs. Sub-page reality.
3 Impact Weight: 20 / 100
15% BS

The homepage H1 ‘WHICH BEST DESCRIBES YOU?’ initiates a user-segmentation funnel that successfully delivers on its promises across sub-pages. The transition from the homepage ‘Let’s Connect’ signal to the granular detail in the ‘How to Use’ sub-page (dosing schedules and injection site maps) shows minimal drift. One minor inconsistency is the high-level promise of ‘independence’ versus the technical reality of ‘supervised injections’ and ‘injection-site reactions’ detailed later. Overall, the content is highly aligned with the primary signal of being an ‘Official Patient Website.’

Identify the current state and friction diagnosis of your specific business model. Generate your Executive SEO Strategy to quantify the financial or conversion cost of strategic misalignment.

Trust & Proof Verifiable evidence vs. Trust Theatre.
4 Impact Weight: 20 / 100
20% BS

Trust is established through ‘HPP STARs’ (named patient advocates like Becky, Sharon, and Ray), though these are internal brand assets rather than independent third-party reviewers. The site lists a review_count of 1 on sub-pages without verified external links, which functions as mild trust theatre. However, the presence of specific proof paths, such as the US Prescribing Information and links to the official HPP Registry, provides significant regulatory validation that counters marketing fluff.

Proof density is high, with a strong ratio of technical safety data to marketing claims. The ‘How to Use’ page provides measurable technical outcomes, such as ‘resolve within a week’ for ISRs and weight-based dosing calculations. The site cites two specific proof paths (Prescribing Information and HPP Registry) on almost every page, ensuring that every marketing assertion is tethered to a regulatory document. The presence of a starter kit with a ‘Symptom Tracker and Log’ further demonstrates a focus on substance over air.

To evaluate URL identity stability and multilingual coherence, review the Yoast Identity Stability audit. View the Yoast Identity Stability Audit for a practical example of canonical alignment and language layer integrity.

Commodity Fingerprint Detection of industry clichés/templates.
5 Impact Weight: 15 / 100
33% BS

The site uses industry-standard cliches such as ‘where science meets compassion’ archetypes and ‘patient support program’ templates. The value proposition is unique to the molecule (asfotase alfa) and the rare disease it treats, making it impossible to copy-paste onto a generic competitor’s site. Boilerplate sections like ‘About OneSource’ and ‘Resources for Injection’ are functional but follow a standard pharmaceutical ‘starter kit’ template fingerprint. The ‘Peer Connects’ branding is a common pharma tactic to build community authority.

Identity & Authority Expert verifiability & Schema depth.
10 Impact Weight: 15 / 100
67% BS

There is a notable technical authority gap as the schema_json is null across all crawled pages, missing a critical opportunity to define Organization or Drug schema. While patient ‘Stars’ are named, they lack a digital footprint in structured data, appearing only as text/image assets. The technical implementation is further hampered by a broken heading hierarchy on the homepage, where eleven identical H2 tags (‘We recommend THAT YOU…’) create an incoherent structural map for search crawlers.

The site claims STRENSIQ is the ‘first and only’ treatment for HPP, a bold performance claim that is supported by the specific indication text rather than vague marketing. Testimonials from ‘HPP Stars’ make efficacy-adjacent claims (e.g., ‘finding his sense of independence’) which are technically buffered by heavy safety disclosures to meet regulatory standards. The disconnect between the ’empowerment’ marketing tone and the clinical reality of ‘serious side effects’ is handled via the mandatory Boxed Warning placement.

Medical Devices, Pharma & Biotech BS: STRENSIQ (Alexion Pharmaceuticals, Inc.) (strensiq.com)

BS: 32/ 100

The content perfectly aligns with the Pharma and Biotech category, focusing on a specific rare disease (HPP) and its associated prescription treatment. The inclusion of Boxed WARNINGS, detailed Prescribing Information, and pharmacovigilance reporting mechanisms (FDA MedWatch) confirms high industry compliance.

Before embeddings, before entities, before retrieval — the crawler must reach the text. Open the Crawlability & Indexation Guide to learn how access failures erase meaning long before interpretation begins.

“The score of 32 reflects a site that is mostly substance-driven. The points were primarily triggered by Technical Gaps (missing schema, broken H2 hierarchy), Repetition (repetitive quiz UI), and Commodity Templates (standard pharma support programs). The score remains low (low BS) because the pharmaceutical industry’s regulatory floor prevents the type of generic, unsubstantiated fluff found in less regulated B2B or consumer categories.”

Verified Analysis Date: May 25, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result
Get a Strategic Holistic View
FREE TOOLS
BUSINESS STRATEGY

Business Intelligence Engine

×
AI VISIBILITY